MedTrace Logo

Real World Data on Gi(l)Otrif® Dose Adjustment

NCT02751879 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-24
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Italy
  • Japan
  • Mexico
  • Poland
  • Singapore
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751879 on ClinicalTrials.gov